Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia

Shirli Tay  
Washington University School of Medicine in St. Louis

Gayan S. De Silva  
Washington University School of Medicine in St. Louis

Connor M. Engel  
Washington University School of Medicine in St. Louis

Nikolai Harroun  
Washington University School of Medicine in St. Louis

Amanda S. Penrose  
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Tay, Shirli; De Silva, Gayan S.; Engel, Connor M.; Harroun, Nikolai; Penrose, Amanda S.; Desai, Kshitij A.; Yan, Yan; Semenkovich, Clay F.; and Zayed, Mohamed A., "Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia." Scientific Reports. 11, 1. 19272 (2021).  
https://digitalcommons.wustl.edu/open_access_pubs/10924

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Prevalence of elevated serum fatty acid synthase in chronic limb-threatening ischemia

Shirli Tay1, Gayan S. De Silva1, Connor M. Engel1, Nikolai Harroun1, Amanda S. Penrose1, Kshitij A. Desai1, Yan Yan2, Clay F. Semenkovich3 & Mohamed A. Zayed1,4,5,6,*

There are currently no serum-based evaluations that can corroborate the severity of peripheral artery disease (PAD). In this cross-sectional study, we assessed the prevalence of elevated serum fatty acid synthase (cFAS) in patients with chronic limb-threatening ischemia (CLTI) and evaluated the accuracy of its use in detecting this condition. Preoperative fasting serum samples from 87 patients undergoing vascular intervention were collected between October 2014 and September 2016. Median age was 62 years, with 56 (64%) men, and 32 (37%) with CLTI. We found that elevated cFAS content (OR 1.17; 95% CI 1.04–1.31), type 2 diabetes (T2D; OR 5.22; 95% CI 1.77–15.4), and smoking (OR 3.53; 95% CI 1.19–10.5) were independently associated with CLTI and could detect the presence of CLTI with 83% accuracy (95% CI 0.74–0.92). Furthermore, serum FAS content was positively correlated with FAS content in femoral artery plaque in patients with severe PAD ($R^2 = 0.22; P = 0.023$). Finally, significantly higher co-localization of FAS and ApoB were observed within lower extremity arterial media ($P < .001$). Our findings indicate that serum FAS content is a marker for disease severity in patients with PAD, independent of concomitant T2D and smoking, and may play a key role in FAS and ApoB peripheral plaque progression.

Peripheral artery disease (PAD) impacts 12 million people in the US1. Among them at least 1 in 10 will progress to develop chronic limb-threatening ischemia (CLTI)2, a condition characterized by severe lower extremity arterial insufficiency, rest pain, non-healing wounds/ulcers, and gangrene3,4. Treatment of incident cases of CLTI is associated with high costs that exceed $100–300 million per year2,5–7. Despite the high level of management required for patients with CLTI, it is reported that up to 70% will still develop disease-related complications, and ultimately receive an extremity amputation5,8,9. In order to improve prognosis, the Global Vascular Guidelines recently highlighted the need for early diagnosis and aggressive medical management of patients with CLTI—particularly among those with cardiovascular risk factors such as type 2 diabetes (T2D)3. Therefore, an accurate biochemical serum diagnostic strategy that can identify individuals with PAD who are at higher risk of progression to CLTI would be immensely beneficial for prompt diagnosis and treatment in order to reduce disease-related morbidity3.

Fatty acid synthase (FAS) is an essential enzyme that regulates de novo lipogenesis in various organ systems including cardiovascular tissue10–12. We previously discovered that serum circulating FAS (cFAS) was elevated in patients with atherosclerotic carotid artery stenosis, and FAS content in carotid plaque was higher in maximally diseased segments13. Interestingly, it was also observed that cFAS predominately fractionated with serum LDL cholesterol and co-immunoprecipitated with apolipoprotein B (ApoB; the dominant protein in LDL particles)14,15. These findings suggested that LDL may be a cFAS carrier that distributes it to peripheral arterial tissue that is prone to atheroprogression13, and that cFAS may be an important marker for disease severity.

Here we sought to determine whether serum cFAS could accurately distinguish between patients with or without CLTI. We hypothesized that higher serum cFAS is an indicator of CLTI, and that FAS localized to peripheral arterial tissue is associated with higher atherosclerotic plaque burden.
Results

Patient characteristics. From October 2014 to September 2016, 431 patients were enrolled in the Washington University School of Medicine Vascular Surgery Biobank. Patients excluded from this study (n = 325) did not provide adequate volume of fasting serum or did not have a recorded ankle-brachial index (ABI) within 3 months of their planned elective operative intervention (Fig. 1). Among the 87 patients who were included in this study the median age was 62 years (IQR 49–68 years) with 56 (64%) male, 71 (82%) Caucasian, 32 (37%) had CLTI, and 32 (37%) had T2D (Table 1).

At baseline, patients with CLTI had higher levels of serum cFAS content (7.03 vs. 3.02; P < 0.001), were older (63 vs. 59 years; P = 0.007), more likely to be current smokers (50% vs. 25%; P = 0.02), have concomitant T2D (63% vs. 22%; P < 0.001), and hypertension (81% vs. 53%; P = 0.008) compared to patients without CLTI. Serum cFAS enzyme activity was analyzed in a subset of 63 patients but no significant difference was found between CLTI and non-CLTI patients (0.65 vs. 0.54 pmol; P = 0.75).

Independent factors and accuracy of detecting CLTI. On multivariable analysis, CLTI was found to be significantly associated with cFAS content (OR 1.17; 95% CI 1.04–1.31), T2D (OR 5.22; 95% CI 1.77–15.4), and smoking (OR 3.53; 95% CI 1.19–10.5; Supplementary Table 1, Fig. 1). When adjusted for age and sex, cFAS content (OR 1.16; 95% CI 1.02–1.31), T2D (OR 3.70; 95% CI 1.21–11.3), and smoking (OR 3.32; 95% CI 1.11–9.96) remained significant. Area under the receiver-operating characteristic curve (AUC) demonstrated that cFAS content, T2D, and smoking status were able to distinguish CLTI patients with 83% accuracy (95% CI 0.74–0.92; Fig. 2a). When adjusted for age and sex, the model improved marginally to 84% (95% CI 0.76–0.93; Fig. 2b). There were no significant interactions and Hosmer–Lemeshow χ² test demonstrated proper fit (P = 0.17).

Multivariable logistic regression comparing patients without PAD (n = 20) and patients with CLTI (n = 32) showed no significant association with cFAS content, T2D, or smoking. When comparing patients with Rutherford classes 0–3 (n = 27) and Rutherford classes 4–6 (n = 32), only cFAS content was significant (OR 1.14; 95% CI 1.01–1.29).

Sensitivity analysis using data from patients with Rutherford classes 0–6 (n = 59) showed that cFAS content (OR 1.11; 95% CI 1.02–1.21) and T2D (OR 3.5; 95% CI 1.30–9.41) significantly increased the odds of having higher Rutherford classes (Supplementary Table 2). Notably, while this was true for most Rutherford class comparisons, there was no significant difference between Rutherford classes 0–3 versus 4–6. Smoking was not associated with the odds of higher Rutherford classes (P = 0.5).

Serum cFAS was not associated with T2D. Due to the high concomitant rate of T2D with CLTI, we performed a secondary analysis to determine whether serum cFAS content was associated with T2D. Among 32 patients with T2D, 22 (69%) patients had diabetes complications severity index (DCSI) score ≥ 5 and 15 (47%) were dependent on insulin (Supplementary Table 3). Multivariable analysis demonstrated that T2D was significantly associated with CLTI (OR 14; 95% CI 2.8–68) and CKD (OR 40; 95% CI 8.3–196). To better determine the effects of cFAS content on T2D, we removed CLTI as a variable and observed that T2D alone was associated with age (OR 1.06; 95% CI 1.01–1.11), sex (OR 0.18 for male; 95% CI 0.04–0.83), and CKD (OR 24; 95% CI 5.9–98.2). Notably, serum cFAS content was not associated with T2D (OR 1.06; 95% CI 0.95–1.19; Supplementary Table 4). Finally, we found no significant difference in cFAS enzyme activity between patients with and without T2D (0.56 vs. 0.56 pmol; P = 0.7).
Correlation between serum cFAS and femoral plaque FAS. In a subset of patients with severe PAD (Rutherford 3–5), we evaluated whether serum cFAS content correlated with FAS content in femoral endarterectomy plaque tissue. Among these 23 patients, 16 (70%) were male, 14 (61%) had CLTI, and 10 (43%) had T2D (Supplementary Table 5). Linear regression demonstrated positive correlation between FAS content in the serum and in plaque tissue ($R^2 = 0.22; P = 0.023$; Fig. 3a). When comparing patients with and without CLTI (Rutherford 4–5 vs. Rutherford 3), there was no significant difference in serum cFAS content (0.9 vs. 1.09; $P = 0.26$) or plaque tissue FAS (9.91 vs. 10.58; $P = 0.75$; Supplementary Fig. 1). In contrast, when comparing patients with

| Characteristics                  | All patients n = 87 | CLTI n = 32 | No CLTI n = 55 | P value |
|----------------------------------|---------------------|-------------|----------------|---------|
| cFAS content                     | 4.11 (2.29–7.48)    | 7.03 (3.33–10.33) | 3.02 (1.86–5.45) | < 0.001* |
| Age—median—years                 | 62 (49–68)          | 63 (59–69)  | 59 (30–67)     | 0.007*  |
| Sex—no. (%)                      |                     |             | 0.78†          |         |
| Male                             | 56 (64.4)           | 20 (62.5)   | 36 (65.5)      |         |
| Female                           | 31 (35.6)           | 12 (37.5)   | 19 (34.6)      |         |
| BMI, median—kg/m²                | 29.4 (23.5–33.1)    | 26.8 (22.7–34.3) | 29.7 (23.3–32.3) | 0.66*  |
| T2D—no. (%)                      | 32 (36.8)           | 20 (62.5)   | 12 (21.8)      | < 0.001† |
| DCSI score ≥ 5                   | 22 (68.8)           | 14 (70)     | 8 (66.7)       | 1†      |
| Insulin use                      | 15 (46.9)           | 11 (55)     | 4 (33)         | 0.29†   |
| CKD—no. (%)                      | 33 (37.9)           | 15 (46.9)   | 18 (32.7)      | 0.19†   |
| CKD 1–3                          | 28 (84.8)           | 11 (73.3)   | 17 (94.4)      |         |
| CKD 4–5                          | 5 (15.2)            | 4 (26.7)    | 1 (5.6)        |         |
| Hyperlipidemia—no. (%)           | 40 (46)             | 18 (56.3)   | 22 (40)        | 0.14†   |
| HTN—no. (%)                      | 55 (63.2)           | 26 (81.3)   | 29 (52.7)      | 0.008†  |
| CHF—no. (%)                      | 13 (14.9)           | 7 (21.9)    | 6 (10.9)       | 0.22†   |
| CAD—no. (%)                      | 29 (33.3)           | 9 (28.1)    | 20 (36.4)      | 0.43†   |
| CAR—no. (%)                      | 11 (12.6)           | 3 (9.4)     | 8 (14.6)       | 0.74†   |
| COPD—no. (%)                     | 14 (16.1)           | 8 (25)      | 6 (10.9)       | 0.085†  |
| Smoking status—no. (%)           |                     |             | 0.020†         |         |
| Never/former                     | 57 (65.5)           | 16 (50)     | 41 (74.6)      |         |
| Current                          | 30 (34.5)           | 16 (50)     | 14 (25.4)      |         |
| PAD status—no. (%)               |                     |             | N/A            |         |
| No PAD                           | 28 (32.2)           | –           | 28 (50.9)      |         |
| Rutherford 0                     | 4 (4.6)             | –           | 4 (7.3)        |         |
| Rutherford 1                     | 0                   | –           | 0              |         |
| Rutherford 2                     | 2 (2.3)             | –           | 2 (3.6)        |         |
| Rutherford 3                     | 21 (24.1)           | –           | 21 (38.2)      |         |
| Rutherford 4                     | 17 (19.5)           | 17 (53.1)   | –              |         |
| Rutherford 5                     | 9 (10.3)            | 9 (28.1)    | –              |         |
| Rutherford 6                     | 6 (6.9)             | 6 (18.8)    | –              |         |
| Procedure—no. (%)                |                     |             | N/A            |         |
| TOSS/venous stab                 | 20 (23)             | 0           | 20 (36.4)      |         |
| AAA/TAA repair                   | 17 (19.5)           | 2 (6.3)     | 15 (27.3)      |         |
| CEA/CAS/dialysis access          | 6 (6.9)             | 1 (3.1)     | 5 (9)          |         |
| LE interventions                 | 44 (50.6)           | 29 (90.6)   | 15 (27.3)      |         |

Table 1. Baseline characteristics of patients who underwent analysis for serum FAS content. AAA: abdominal aortic aneurysm; BMI: body mass index; CAR: carotid artery stenosis; CAS: carotid artery stenting; CEA: carotid endarterectomy; cFAS: serum circulating fatty acid synthase; CHF: congestive heart failure; CKD: chronic kidney disease; CLTI: chronic limb-threatening ischemia; COPD: chronic obstructive pulmonary disease; Current smoker: last smoked within 12 months of vascular procedure; Former smoker: last smoked > 12 months before procedure; HTN: hypertension; LE interventions: lower extremity interventions included endovascular or open procedures and amputation; PAD: peripheral artery disease; T2D: type 2 diabetes mellitus; TAA: thoracic aortic aneurysm; TOS: thoracic outlet syndrome; N/A: not applicable; Continuous variables are presented as medians with interquartile ranges. Categorical variables are presented as frequencies and percentages. *Mann–Whitney U-test. †Chi-square test. ‡Fisher’s Exact test.
and without T2D, both serum cFAS content (1.51 ± 0.75 vs. 0.95 ± 0.29; P = 0.047) and plaque FAS (14.0 ± 4.46 vs. 8.11 ± 4.93; P = 0.013) were significantly higher in patients with T2D compared to no T2D (1.51 ± 0.75 vs. 0.95 ± 0.29; P = 0.047). Similarly, femoral plaque FAS content was significantly higher in patients with T2D (14.0 ± 4.46 vs. 8.11 ± 4.93; P = 0.013). Boxplot indicates interquartile range (IQR), median (horizontal line within box), and 1.5 IQR of upper quartile (top whisker) and lower quartile (bottom whisker). cFAS and plaque FAS content were expressed as ratios relative to total serum or plaque protein content, respectively. *P < 0.05.

Comparison of free fatty acid content in femoral plaque. Saturated (SFA) and unsaturated free fatty acid (UFA) content were evaluated in femoral endarterectomy plaque specimens from patients with severe PAD (n = 22). Among these patients, 7 patients were Rutherford 3, 13 patients were Rutherford 4, and 2 patients were Rutherford 5. Overall, 10 patients had T2D. We observed no correlation between FFA and FAS content in femoral plaque of patients with severe PAD with or without T2D (Supplementary Table 6). Similarly, there was no correlation between FFA and serum cFAS content in this cohort (Supplementary Table 7).

Co-localization of FAS and ApoB in lower extremity arterial wall. To evaluate whether tissue FAS and ApoB co-localize in peripheral arterial tissue, we analyzed arterial wall segments from ischemic amputated lower extremities of patients with CLTI (4 with T2D and 4 without T2D). Randomly selected representative arterial segments reflecting the group mean trends were evaluated (Fig. 4a,b). When compared to CLTI patients without T2D, univariable analysis demonstrated that patients with T2D had significantly higher ApoB content (P = 0.021; Fig. 4c) and co-localization of FAS and ApoB (P = 0.043; Fig. 4d) in the arterial wall medial layer.
However, there was no difference in FAS localization between CLTI patients with and without T2D ($P=0.56$; Fig. 4e).

Two-way ANOVA demonstrated no difference in signals in the intima layer (Fig. 5a). In the media layer, there were significantly higher ApoB and FAS:ApoB co-localization signal ($P<0.001$) in patients with CLTI and T2D (Fig. 5b). In the adventitia layer, there were significantly higher ApoB signals in patients without T2D ($P=0.026$), but no difference in FAS ($P=0.40$) or co-localization signal ($P=0.13$; Fig. 5c).

Discussion

We found that serum cFAS content is a marker of CLTI, independent of a concomitant diagnosis of T2D or smoking status. After adjusting for age and sex, each unit increase in serum cFAS content increased the odds of CLTI by 16%, while the presence of T2D and smoking increased the odds of CLTI by 270% and 232%, respectively. In fact, using cFAS content, T2D, and smoking status as markers of disease provided 83% accuracy in distinguishing which patients had CLTI. We also found that for every unit increase in cFAS content, the odds of having a more severe Rutherford classification correspondingly increased by 11%. Notably, when we compared Rutherford classes, we found no difference in cFAS content and T2D between Rutherford classes 0–3 and 4–6, while any other class comparisons yielded significant differences. This shows that serum cFAS content not only correlates positively to increasing severity of PAD, it may also be an important differentiator of impending tissue loss.

In patients with known PAD, CLTI may present when there is clinical progression in disease severity. However, in a large proportion of patients, primary CLTI with no prior diagnosis of PAD can also develop, and T2D appears to be the strongest risk factor for its occurrence (OR 7.45)$^{2,3}$. It is common belief that in patients with primary CLTI, early diagnosis and implementation of aggressive medical management can improve the overall prognosis of the disease. However, patients with CLTI are heterogeneous, and historically this dilemma has contributed to the lack of high-quality epidemiological data on prevalence, incidence, and predictors of CLTI$^1$. Further confounding is the observation that patients who undergo amputation as a complication related to CLTI are at increased risk of premature death and are therefore more likely to be missing from population-based
β-oxidation of fatty acids through activation of PPARα under nutrient-deficient conditions. But recent studies have implicated serum cFAS as a biomarker for disease progression including various forms of human cancer and metastatic disease. Future studies may further explore therapeutic targeting of FAS in mice causes embryonic lethality, confirming its essential role in early tissue development and embryogenesis. However, in adult tissue, FAS was traditionally viewed as a housekeeping enzyme that contributes to hepatic triglyceride production for energy storage during nutrient-replete conditions and promotes β-oxidation of fatty acids through activation of PPARα under nutrient-deficient conditions. Our group previously discovered serum cFAS is elevated in individuals with severe atherosclerosis. In a cohort of 39 patients, we observed that cFAS was significantly elevated in individuals with severe carotid artery stenosis and T2D. We found that cFAS correlated not only with serum glucose levels but also with saturated fatty acids in carotid plaque segments. Since patients with carotid artery stenosis have elevated risks of also developing advanced PAD, the current study of serum cFAS in patients with CLTI was a natural extension of our investigation. Here, we similarly observed that serum cFAS content was indeed higher in patients with CLTI. These findings across both studies suggest that elevated serum cFAS in patients with atherosclerosis in the peripheral arterial system is indicative of disease severity.

In tissue, FAS exists as a homodimer of 273 kDa subunits, and is essential for de novo synthesis of saturated fatty acids from simple precursors such as acetyl-CoA, malonyl-CoA, and NADPH. Whole-body knockout of FAS in mice causes embryonic lethality, confirming its essential role in early tissue development and embryogenesis. However, in adult tissue, FAS was traditionally viewed as a housekeeping enzyme that contributes to hepatic triglyceride production for energy storage during nutrient-replete conditions and promotes β-oxidation of fatty acids through activation of PPARα under nutrient-deficient conditions. But recent studies confirm a broader role for FAS in vascular tissue regulation. For example, FAS content is critical for endothelial cell nitric-oxide synthase (eNOS) signaling and cellular barrier function, and is decreased in the aortic tissue of Db/Db mice. In macrophages, FAS is essential for prevention of diet-induced insulin resistance and recruitment of macrophages to adipose tissue. Our study builds upon this body of knowledge and demonstrates that FAS content in peripheral arterial tissue is variable depending on disease severity, and also correlates with serum cFAS content. Interestingly, our study did not find any correlation between cFAS and FFAs in femoral plaque specimens, including SFA 16:0 and 18:0. Prior studies demonstrated that dietary intake and T2D can independently impact FFA content in vivo, but whether this is directed by FAS-mediated de novo synthesis of SFAs in the peripheral arterial tissue remains to be elucidated.

In this study we observed elevated serum cFAS content in patients with CLTI, but no difference in serum cFAS enzyme activity. While it is unknown whether increased cFAS content or its biochemical enzymatic substrates in the serum are primarily responsible for conferring the presumed increased risk of peripheral arterial atheroprogression, our findings suggest serum cFAS of patients with advanced PAD is biochemically active. Similarly, other studies have implicated serum cFAS as a biomarker for disease progression including various forms of human cancer and metastatic disease. Future studies may further explore therapeutic targeting of cFAS enzyme activity, particularly in populations with increased cFAS content, such as patients with CLTI as our data demonstrates. Based on our prior findings that serum cFAS co-immunoprecipitated with ApoB in LDL cholesterol fraction from patients with carotid artery stenosis, we hypothesized that FAS in arterial tissue may also co-localize with...
ApoB in patients with CLTI. Indeed, co-localization of FAS and ApoB staining appeared most notable in the arterial media where lipid cores emerge leading to atheroprogression. These findings support our previously reported model that FAS produced by the liver is extruded into the blood stream in a semi-soluble form and conjugated to ApoB in non-HDL cholesterol particles such as VLDL and LDL. Ultimately, intravascular LDL particles traverse the endothelium along with their cFAS cargo and deliver it to the sub-endothelial media layer to contribute to accelerated plaque formation. Additional studies are underway to further confirm this proposed molecular mechanism for peripheral atheroprogression.

We acknowledge that our study has limitations. First, this is a cross-sectional study which allowed us to evaluate serum cFAS as a marker for CLTI. Future studies using prospectively recruited study subjects, including health volunteers with no evidence of vascular disease, will be better suited to determine sensitivity and specificity of cFAS as an indicative biomarker that can predict disease progression. Second, due to the relatively small sample size, our study was not have sufficiently powered to evaluate differences in cFAS in patients with variable severity of PAD (different Rutherford classes and patients with no PAD) as well as other important comorbidities such as CKD. Further studies using a larger cohort may provide better accuracy and validity of our findings, and also provide additional information regarding how the extent of inflow versus outflow disease in patients with CLTI impacts serum cFAS levels. Finally, patient characteristics relied on chart review which may inadvertently contain misclassification errors. We attempted to set clearly defined criteria and revisited patient charts to confirm the quality and accuracy of the data to the best of our ability.

In conclusion, we found that serum cFAS content was significantly associated with CLTI, independent of concomitant diagnosis of T2D and smoking status. Using serum cFAS content, T2D, and smoking status provided high accuracy in distinguishing patients with CLTI. Furthermore, we demonstrated that serum cFAS content positively correlated with FAS content in femoral artery plaque tissue, and that FAS and ApoB co-localized in peripheral arterial wall medial layer. Our findings suggest that higher serum FAS may lead to altered FAS content in peripheral arterial tissue and impact atheroprogression in patients with CLTI. Future prospective studies may be able to determine whether serum cFAS content is a reliable serum-based diagnostic and predictive biomarker for patients with advanced PAD and CLTI.

Methods

All methods were performed in accordance with institutional guidelines and regulations. All experimental protocols were approved by Institutional Review Board (IRB) at Washington University School of Medicine in St. Louis.

Serum and tissue samples. We analyzed preoperative fasting serum from patients enrolled in an IRB-approved Vascular Surgery Biobank (see Supplementary information). Consecutive adults (aged ≥18 years) who underwent planned elective vascular surgery operative interventions from October 2014 to September 2016 were included. Individuals with CLTI who were undergoing lower extremity revascularization procedures were included in the analysis. Individuals without CLTI who were undergoing operative intervention for lower extremity revascularization, abdominal aortic aneurysm repair, carotid stenosis repair, neurogenic thoracic outlet syndrome (TOS) repair, or venous stripping or ablation were also included as non-CLTI controls. In a subset of patients with CLTI, intraoperative femoral artery endarterectomy plaque specimens and peripheral arterial segments from amputated lower extremities were also collected. All patients provided written informed consent to participate in this study.

Variables of interest. We collected patient-level data such as demographics, disease severity, comorbidities, and medications from chart review. Severity of PAD was categorized as CLTI (Rutherford classes 4–6) and non-CLTI (Rutherford classes 0–3 and no PAD). Using CLTI as dependent variable, we evaluated serum cFAS, patient age, sex, race, comorbidities including T2D, insulin-dependency, and DCSI score (see Supplementary information). Due to the high co-occurrence of CLTI with T2D, we also analyzed a secondary model using T2D as a dependent variable.

cFAS content and enzyme activity. Content of cFAS in the serum and FAS in lower extremity arterial plaque specimens were analyzed using commercially available human FAS ELISA Kit according to manufacturer’s recommendations (Advia Systems Biology Corporation, San Diego, CA; see Supplementary information). cFAS enzyme activity was evaluated using a modification of a previously described assay.

Free fatty acid in femoral plaque of patients with severe PAD. We measured saturated and unsaturated free fatty acid (FFA) in femoral plaque of patients with severe PAD (Rutherford classes 3–5) who are typically candidates for femoral endarterectomy procedures. Modified Bligh-Dyer method was performed as previously described (see Supplementary information). Briefly, plaque tissue was homogenized with lysis buffer prior to the addition of lipid internal standard solution. After phase separation, samples were extracted, vaporized to recover crystallized lipid, and analyzed with mass spectrometry. Each sample was evaluated at least in duplicate.
Co-localization of FAS and ApoB in peripheral arterial segments. We collected lower extremity arterial segments from amputated lower extremities of patients with CLTI and T2D and without T2D. Popliteal, anterior tibial, posterior tibial, and peroneal arterial segments were evaluated with immunofluorescent (IF) staining for FAS and ApoB (see Supplementary information). To quantify the proportion of FAS and ApoB signals within the arterial wall, images of stained arterial segments were digitally separated into intima (beginning of arterial wall to end of internal elastic lamina), media (between internal and external elastic lamina), and adventitia (external elastic lamina to end of arterial wall) using ImageJ software. Pixel threshold for hue was set at red 0–20 for FAS, green 46–120 for ApoB, and yellow 21–45 for co-localization. Pixels beyond the hue threshold were defined as non-colocalized signals. Extraneous autofluorescence (beyond the arterial wall) were excluded from quantification. Signals were reported as a proportion of total signals.

Statistical analysis. We summarized continuous variables with medians and interquartile ranges, and categorical variables with frequencies and percentages. Group comparisons were performed with Mann–Whitney U-test, Chi-square, or Fisher’s Exact test accordingly.

To evaluate FAS as a marker for CLTI, we performed multivariable logistic regression using CLTI as a dependent variable. Independent variables that were clinically important and statistically significant based on univariable analysis were included in logistic regression. No more than five independent variables were selected at a time using backward elimination. Sensitivity analysis was performed with ordinal logistic regression and excluded patients without PAD. To assess classification accuracy, we analyzed AUC. AUC values closer to 1 indicate a greater accuracy in distinguishing outcome of interest. To evaluate co-localization of FAS and ApoB, immunofluorescent staining signals were analyzed using two-way analysis of variance (ANOVA). If F test was significant, Tukey’s test identified the arterial layer that differed from the others.

All tests were two-sided and P < 0.05 was considered significant. Hosmer–Lemeshow χ² test with P > 0.05 indicates appropriate fit. All statistical analyses were performed with SAS Software version 9.4 (SAS Institute, Cary, NC). All graphs were generated with Stata 16.1 (StataCorp, College Station, TX).

Data availability The datasets generated during the current study are not publicly available due to the protection of patient privacy but are available from the corresponding author on reasonable request.

Received: 30 May 2021; Accepted: 30 August 2021
Published online: 29 September 2021

References
1. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26, 3333–3341 (2003).
2. Nehler, M. R. et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J. Vasc. Surg. 60, 686–695.e2 (2014).
3. Conte, M. S. et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur. J. Vasc. Endovasc. Surg. 58, S1-S109.e33 (2019).
4. Rutherford, R. B. et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J. Vasc. Surg. 26, 517–538 (1997).
5. Dua, A. et al. Preventable complications driving rising costs in management of patients with critical limb ischemia. Ann. Vasc. Surg. 33, 144–148 (2016).
6. Martinez, R. A. et al. Nationally representative readmission factors in patients with claudication and critical limb ischemia. Ann. Vasc. Surg. 52, 96–107 (2018).
7. Agarwal, S., Sud, K. & Shishehbor, M. H. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: From 2003–2011. J. Am. Coll. Cardiol. 67, 1901–1913 (2016).
8. Peacock, J. M. et al. The incidence and health economic burden of ischemic amputation in Minnesota, 2005–2008. Prev. Chronic. Dis. 8, A141 (2011).
9. Ramsey, S. D. et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22, 382–387 (1999).
10. Menendez, J. A., Vazquez-Martín, A., Ortega, F. J. & Fernandez-Real, J. M. Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer. Clin. Chem. 55, 425–438 (2009).
11. Witkowski, A., Joshi, A. K. & Smith, S. Coupling of the de novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria. J. Biol. Chem. 282, 14178–14185 (2007).
12. Semenkovich, C. F. Regulation of fatty acid synthase (FAS). Prog. Lipid Res. 36, 43–53 (1997).
13. De Silva, G. S. et al. Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated. Atherosclerosis 287, 84–98 (2019).
14. Tabin, J., Williams, K. J. & Boren, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Circulation 116, 1832–1844 (2007).
15. Rader, D. J. & Daugherty, A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 451, 904–913 (2008).
16. Chirala, S. S., Jayakumar, A., Gu, Z.-W. & Wakil, S. J. Human fatty acid synthase: Role of interdomain in the formation of catalytically active synthase dimer. Proc. Natl. Acad. Sci. 98, 3104–3108 (2001).
17. Wakil, S. J. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28, 4523–4530 (1989).
18. Chirala, S. S. et al. Fatty acid synthase is essential in embryonic development: Fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc. Natl. Acad. Sci. 100, 6358–6363 (2003).
19. Jensen-Urstad, A. P. L. & Semenkovich, C. F. Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger? Biochem. Biophys. Acta BBA Mol. Cell. Biol. Lipids 1821, 747–753 (2012).
20. Wei, X. et al. De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. J. Biol. Chem. 286, 2933–2941 (2011).
21. Wei, X. et al. Fatty acid synthase confers the plasma membrane for inflammation in diabetes. Nature 539, 294–298 (2016).
22. King, J. B., Lemaitre, R. N. & Kestin, M. Effect of a low-fat diet on fatty acid composition in red cells, plasma phospholipids, and cholesterol esters: Investigation of a biomarker of total fat intake. Am. J. Clin. Nutr. 83, 227–236 (2006).
23. Forouhi, N. G. et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: The EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2, 810–818 (2014).
24. Zhang, M.-H. et al. Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. *BMC Endocr. Disord.* **20**, 156 (2020).
25. Rashid, A. et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. *Am. J. Pathol.* **150**, 201–208 (1997).
26. Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat. Rev. Cancer* **7**, 763–777 (2007).
27. Kuhajda, F. P. Fatty acid synthase and cancer: New application of an old pathway. *Cancer Res.* **66**, 5977–5980 (2006).
28. Wang, Y. Y., Kuhajda, F. P., Sokoll, L. J. & Chan, D. W. Two-site ELISA for the quantitative determination of fatty acid synthase. *Clin. Chim. Acta* **304**, 107–115 (2001).
29. Young, B. A. et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. *Am. J. Manag. Care* **14**, 15–23 (2008).
30. Ullman, A. H. & White, H. B. [17] Assay of fatty acid synthase using a bicyclic dione as substrate. In *Methods in Enzymology*, Vol. 72, 303–306 (Elsevier, 1981).
31. Chakravarthy, M. V. et al. Identification of a physiologically relevant endogenous ligand for PPARα in liver. *Cell* **138**, 476–488 (2009).
32. NIH Image to ImageJ: 25 years of image analysis | Nature Methods. [https://www.nature.com/articles/nmeth.2089](https://www.nature.com/articles/nmeth.2089).
33. Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* **143**, 29–36 (1982).

**Acknowledgements**

This work was supported by the Washington University School of Medicine Vascular Surgery Biobank Facility. The authors thank Dr. Chao Yang and Dr. Chenglong Li for their assistance with collection, preparation, and processing of Biobank Core Facility research samples. The authors also thank Dr. Xiaohua Jin for her critical suggestions and critiques.

**Author contributions**

M.A.Z. conceived the design and conduct of the study. G.S.D., C.M.E., N.H., A.S.P., and K.A.D. performed experiments. S.T., C.M.E., and A.S.P. collected the data. S.T. and Y.Y. analyzed and interpreted the data. S.T. wrote the manuscript with major contributions from M.A.Z. and C.F.S. All authors reviewed and approved the final version of the manuscript.

**Funding**

This work was supported by grants from the Vascular Cures Foundation Wylie Scholar Award (MAZ), American Surgical Association Research Fellowship Award (MAZ), Society for Vascular Surgery Foundation Investigator Award (MAZ), Washington University School of Medicine Diabetes Research Center NIH/NIDDK P30 DK020589 (MAZ), NIH/NIDDK R01 DK101392 (CFS), NIH/NHLBI K08 HL132060 (MAZ), and NIH/NHLBI R01 HL153262 (MAZ).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1038/s41598-021-98479-7](https://doi.org/10.1038/s41598-021-98479-7).

**Correspondence** and requests for materials should be addressed to M.A.Z.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access](https://creativecommons.org/licenses/by/4.0/) This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2021